Biologicals in atopic disease in pregnancy: An EAACI position paper
| العنوان: | Biologicals in atopic disease in pregnancy: An EAACI position paper |
|---|---|
| المؤلفون: | Adam Chaker, Zsolt Szépfalusi, Juan José Yepes-Nuñez, Onur Boyman, A. Vultaggio, Alexia Chatzipetrou, Oscar Palomares, Cezmi A. Akdis, Marek Jutel, Eva Untersmayr, Andrea Matucci, Mohammad Alsalamah, Alanna Marson, Sevim Bavbek, Paula Kauppi, Birgit Pfaller, Barbara Rogala, Antonios G.A. Kolios, Sarah Bendien, Susan Chan, Ioana Agache, Thomas Eiwegger, Carmen Li, Apostolos Bossios, George Du Toit |
| المساهمون: | HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, Helsinki University Hospital Area, University of Helsinki, University of Zurich, Eiwegger, Thomas |
| المصدر: | Allergy. 76:71-89 |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Allergy, Omalizumab, GUIDELINES, Inflammatory bowel disease, Biological Factors, 0302 clinical medicine, 10183 Swiss Institute of Allergy and Asthma Research, Multicenter Studies as Topic, Immunology and Allergy, atopic dermatitis, 10177 Dermatology Clinic, Atopic dermatitis, CROHNS-DISEASE, 3. Good health, biologicals, 2723 Immunology and Allergy, Female, Rituximab, pregnancy, medicine.drug, medicine.medical_specialty, 1ST TRIMESTER, Immunology, 610 Medicine & health, OMALIZUMAB USE, Dermatitis, Atopic, 03 medical and health sciences, MANAGEMENT, medicine, Humans, RITUXIMAB, REGULATORY T-CELLS, Intensive care medicine, Asthma, Biological Products, 2403 Immunology, Pregnancy, business.industry, Infant, Newborn, asthma, medicine.disease, body regions, 030104 developmental biology, 030228 respiratory system, 3121 General medicine, internal medicine and other clinical medicine, 10033 Clinic for Immunology, MODIFYING ANTIRHEUMATIC DRUGS, Position paper, business, INFLAMMATORY-BOWEL-DISEASE |
| الوصف: | Biologicals have transformed the management of severe disease phenotypes in asthma, atopic dermatitis, and chronic spontaneous urticaria. As a result, the number of approved biologicals for the treatment of atopic diseases is continuously increasing. Although atopic diseases are among the most common diseases in the reproductive age, investigations, and information on half-life, pharmacokinetics defining the neonatal Fc receptors (FcRn) and most important safety of biologicals in pregnancy are lacking. Given the complex sequence of immunological events that regulate conception, fetal development, and the intrauterine and postnatal maturation of the immune system, this information is of utmost importance. We conducted a systematic review on biologicals in pregnancy for indications of atopic diseases. Evidence in this field is scare and mainly reserved to reports on the usage of omalizumab. This lack of evidence demands the establishment of a multidisciplinary approach for the management of pregnant women who receive biologicals and multicenter registries for long-term follow-up, drug trial designs suitable for women in the reproductive age, and better experimental models that represent the human situation. Due to the very long half-life of biologicals, pre-conception counseling, and health care provider education is crucial to offer the best care for mother and fetus. This position paper integrates available data on safety of biologicals during pregnancy in atopic diseases via a systematic review with a detailed review on immunological considerations how inhibition of different pathways may impact pregnancy. |
| تدمد: | 1398-9995 0105-4538 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de841b33045dacee0f5de24aa741cf25 https://doi.org/10.1111/all.14282 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....de841b33045dacee0f5de24aa741cf25 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13989995 01054538 |
|---|